The acquisition transforms Biogen's near-term growth profile with two approved products and a pipeline catalyst in nephrology. Monitor Q2 2026 earnings for updated financial guidance incorporating Apellis, and track SYFOVRE sales trajectory for CVR payout potential. The deal removes Apellis overhang and provides a clear revenue growth driver beyond Biogen's legacy neurology franchise.
Price Chart
Executive Summary
Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in contingent value rights, adding two commercial products (EMPAVELI and SYFOVRE) that generated $689 million in combined 2025 net product revenue. The deal is expected to be accretive to Biogen's non-GAAP EPS in 2027 and materially increase its non-GAAP EPS CAGR through the end of the decade, while expanding Biogen into nephrology ahead of a key Phase 3 readout for felzartamab in 2027.
Key Financial Metrics
Key Facts
- Biogen acquired Apellis for $41 per share in cash plus up to $4 per share in CVRs tied to SYFOVRE sales thresholds.
- Approximately 105.7 million shares (82.4% of outstanding) were tendered; remaining shares converted at the same price.
- EMPAVELI and SYFOVRE generated $689 million in combined net product revenue in 2025.
- The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and materially increase non-GAAP EPS CAGR through the end of the decade.
- Apellis brings established nephrology commercial infrastructure to support felzartamab launch, with first Phase 3 readout in antibody-mediated rejection expected in H1 2027.
Financial Impact
Total consideration of approximately $4.3 billion in cash plus up to $420 million in CVRs based on 105.7M shares tendered at $41/share plus $4/share CVR; combined acquired products had $689M in 2025 revenue.
Risk Factors
- Integration risk: realizing expected synergies and maintaining Apellis product sales momentum.
- SYFOVRE faces competition from Iveric Bio's avacincaptad pegol (Izervay) in geographic atrophy.
- CVR payments depend on achieving SYFOVRE net sales thresholds, which may not be met.
- Felzartamab Phase 3 readout in 2027 is binary and may not succeed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294955 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access